Burden of Multidrug Resistant Escherichia coli among Patients with Urinary Tract Infections in a Tertiary Care Centre- A Retrospective Analysis
Introduction: Multidrug Resistant (MDR) Escherichia coli isolates causing Urinary Tract Infections (UTIs), capable of producing Extended Spectrum Beta Lactamase (ESBL), AmpC beta lactamase and resistance to carbapenems pose serious challenges to the clinicians causing worse clinical scenarios. T...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
JCDR Research and Publications Private Limited
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/78e198c18bdd43aebe7abdbc6122b3d2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction: Multidrug Resistant (MDR) Escherichia coli isolates
causing Urinary Tract Infections (UTIs), capable of producing
Extended Spectrum Beta Lactamase (ESBL), AmpC beta lactamase
and resistance to carbapenems pose serious challenges to the
clinicians causing worse clinical scenarios. The detection of these
isolates has prime importance in infection control and improving
therapeutic management of patients, as their prevalence is increasing
worldwide. Injudicious use of antibiotics has led to selective
pressure, resulting in the emergence of antibiotic resistance in
gram negative bacteria globally. This rise in antimicrobial resistance
has decreased the options for empirical therapy, causing a global
health concern in infections associated with ESBL producing and
AmpC producing isolates.
Aim: To investigate the burden of ESBL producing, AmpC
beta-lactamase producing, carbapenem resistant, and MDR
Escherichia coli isolated from urine samples in a tertiary care
centre.
Materials and Methods: The present retrospective study conducted
from January to December 2019. A total of 10,535 urine samples
were received during the study period, to find out the burden of
drug resistant Escherichia coli isolates in urine samples, analyse
their antibiogram and patients’ socio-demographic information.
Records of microscopic observations to antibiogram of each isolate
was noted down from the register for urine samples, and further
analysed. The data was coded, verified, entered and analysed
using Statistical Package for Social Sciences (SPSS) version 18.0.
Results: Among the total urine samples (10,535), 1434 (13.6%)
Escherichia coli isolates were identified, of which 553 (38.6%)
were found to be ESBL producing, 497 (34.6%) AmpC betalactamase producing, 172 (12%) Carbapenem resistant, and
765 (53.3%) MDR. Majority of the isolates were from the age
group of 51-60 years 288 (20.08%). The least susceptibility of
the isolates was detected against penicillin G 1410 (98.3%),
followed by ampicillin 1160 (80.9%) and cephazolin 74 (67.9%).
Among the MDR isolates, the maximum drug resistance (398,
52%) was seen in penicillin, cephems, quinolones and Folate
pathway antagonist group of antimicrobials.
Conclusion: Identification of the drug resistant isolates is of high
priority and crucial for therapeutic management of the patients,
and infection control. Stringent antimicrobial stewardship policies
and judicious use of antimicrobials can decrease the spread of
antimicrobial resistant genes in the hospital environment. |
|---|